MX2021000805A - Soluciones de complejos de radionuclidos estables y concentradas. - Google Patents

Soluciones de complejos de radionuclidos estables y concentradas.

Info

Publication number
MX2021000805A
MX2021000805A MX2021000805A MX2021000805A MX2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A MX 2021000805 A MX2021000805 A MX 2021000805A
Authority
MX
Mexico
Prior art keywords
stable
complex solutions
radionuclide complex
pharmaceutical product
concentrated
Prior art date
Application number
MX2021000805A
Other languages
English (en)
Spanish (es)
Inventor
Lorenza Fugazza
Daniela Chicco
Donato Barbato
Palo Francesco De
Maurizio Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021000805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by Advanced Accelerator Applications Sa filed Critical Advanced Accelerator Applications Sa
Publication of MX2021000805A publication Critical patent/MX2021000805A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021000805A 2018-07-25 2018-09-25 Soluciones de complejos de radionuclidos estables y concentradas. MX2021000805A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
MX2021000805A true MX2021000805A (es) 2021-05-12

Family

ID=63794577

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000805A MX2021000805A (es) 2018-07-25 2018-09-25 Soluciones de complejos de radionuclidos estables y concentradas.
MX2025012060A MX2025012060A (es) 2018-07-25 2021-01-20 Soluciones de complejos de radionuclidos estables y concentradas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025012060A MX2025012060A (es) 2018-07-25 2021-01-20 Soluciones de complejos de radionuclidos estables y concentradas

Country Status (23)

Country Link
EP (7) EP4545100B1 (cg-RX-API-DMAC7.html)
JP (3) JP7402218B2 (cg-RX-API-DMAC7.html)
KR (4) KR102865113B1 (cg-RX-API-DMAC7.html)
CN (5) CN112584875A (cg-RX-API-DMAC7.html)
AU (7) AU2018433575B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001148A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153630A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000506A2 (cg-RX-API-DMAC7.html)
DE (3) DE202018007006U1 (cg-RX-API-DMAC7.html)
DK (7) DK4640241T3 (cg-RX-API-DMAC7.html)
ES (6) ES3064434T3 (cg-RX-API-DMAC7.html)
FI (7) FI4545101T3 (cg-RX-API-DMAC7.html)
HR (6) HRP20260222T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072720T2 (cg-RX-API-DMAC7.html)
IL (5) IL280314B1 (cg-RX-API-DMAC7.html)
LT (7) LT4541381T (cg-RX-API-DMAC7.html)
MX (2) MX2021000805A (cg-RX-API-DMAC7.html)
PL (6) PL4545100T3 (cg-RX-API-DMAC7.html)
PT (7) PT4541381T (cg-RX-API-DMAC7.html)
RS (7) RS67729B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100645XA (cg-RX-API-DMAC7.html)
SI (6) SI4541381T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020021322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CA3235923A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
WO2018081860A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Also Published As

Publication number Publication date
FI4541381T3 (fi) 2026-04-01
PT4545100T (pt) 2026-02-16
PL4541380T3 (pl) 2026-03-30
AU2022203683B2 (en) 2023-12-21
LT4541379T (lt) 2026-02-10
RS67667B1 (sr) 2026-02-27
ES3065583T3 (en) 2026-05-06
DK4545100T3 (da) 2026-02-23
EP4541380A3 (en) 2025-07-23
RS67755B1 (sr) 2026-03-31
EP4545100B1 (en) 2025-12-10
ES3064434T3 (en) 2026-04-24
ES3064589T3 (en) 2026-04-27
AU2025220852A1 (en) 2025-09-11
DK4545101T3 (da) 2026-03-02
IL280314A (en) 2021-03-25
DE202018007007U1 (de) 2025-11-13
KR20210035855A (ko) 2021-04-01
FI3826686T3 (fi) 2025-08-20
AU2026204487A1 (en) 2026-07-02
AU2025220852B2 (en) 2025-10-23
EP4541379B1 (en) 2025-11-19
WO2020021322A1 (en) 2020-01-30
CN121081692A (zh) 2025-12-09
EP4545101B1 (en) 2025-12-10
DK4541379T3 (da) 2026-02-02
IL319542A (en) 2025-05-01
IL326944A (en) 2026-05-01
LT4545101T (lt) 2026-03-10
RS68308B1 (en) 2026-07-31
JP2025111424A (ja) 2025-07-30
PT4640241T (pt) 2026-07-17
LT3826686T (lt) 2025-08-25
RS67754B1 (sr) 2026-03-31
FI4545101T3 (fi) 2026-02-24
HRP20260237T1 (hr) 2026-04-10
DK3826686T3 (da) 2025-08-25
EP4640241B1 (en) 2026-06-03
HRP20260179T1 (hr) 2026-04-10
EP4541380A2 (en) 2025-04-23
ES3067415T3 (en) 2026-05-21
CN120860272A (zh) 2025-10-31
EP4640241A2 (en) 2025-10-29
AU2022203683A1 (en) 2022-06-16
LT4541381T (lt) 2026-03-25
PT3826686T (pt) 2025-08-04
IL319542B2 (en) 2026-08-01
EP4545100A2 (en) 2025-04-30
PL4541379T3 (pl) 2026-03-23
DK4541381T3 (da) 2026-04-07
SG11202100645XA (en) 2021-02-25
KR102865113B1 (ko) 2025-09-26
DE202018007006U1 (de) 2025-11-13
FI4541379T3 (fi) 2026-02-17
JP2023117417A (ja) 2023-08-23
SI4541380T1 (sl) 2026-04-30
IL319542B1 (en) 2026-04-01
BR112021001148A2 (pt) 2021-04-20
EP3826686B1 (en) 2025-05-21
HRP20260338T1 (hr) 2026-04-10
EP4541379A2 (en) 2025-04-23
CN120860270A (zh) 2025-10-31
IL319541B1 (en) 2025-09-01
PL4541381T3 (pl) 2026-05-11
SI4545101T1 (sl) 2026-04-30
IL280314B1 (en) 2026-07-01
JP2022501313A (ja) 2022-01-06
KR20250017751A (ko) 2025-02-04
KR102932818B1 (ko) 2026-03-03
SI4541379T1 (sl) 2026-03-31
EP4640241A3 (en) 2025-12-10
AU2025204901A1 (en) 2025-07-17
AU2025202231B2 (en) 2026-05-14
MX2025012060A (es) 2025-11-03
CO2021000506A2 (es) 2021-04-19
FI4541380T3 (fi) 2026-03-02
PL3826686T3 (pl) 2025-09-22
ES3038413T3 (en) 2025-10-13
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
KR20240033296A (ko) 2024-03-12
PT4541381T (pt) 2026-03-17
EP4541379A3 (en) 2025-07-23
KR102643582B1 (ko) 2024-03-05
EP4541381B1 (en) 2026-02-04
IL313560A (en) 2024-08-01
DK4640241T3 (da) 2026-07-27
IL319541A (en) 2025-05-01
AU2024201217B2 (en) 2025-02-27
FI4640241T3 (fi) 2026-07-21
HRP20250912T1 (hr) 2025-09-26
PT4545101T (pt) 2026-02-24
IL319541B2 (en) 2026-01-01
PT4541380T (pt) 2026-02-24
HUE072720T2 (hu) 2025-12-28
AU2018433575B2 (en) 2022-07-07
CA3153630A1 (en) 2020-01-30
AU2025202231A1 (en) 2025-04-17
EP4541381A2 (en) 2025-04-23
SI3826686T1 (sl) 2025-09-30
EP4545101A3 (en) 2025-07-23
IL313560B1 (en) 2025-07-01
AU2024201217A1 (en) 2024-03-14
CN120860271A (zh) 2025-10-31
PL4545101T3 (pl) 2026-03-30
AU2018433575A1 (en) 2021-02-11
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
HRP20260100T1 (hr) 2026-04-10
LT4640241T (lt) 2026-07-27
DK4541380T3 (da) 2026-02-23
HRP20260222T1 (hr) 2026-03-27
LT4545100T (lt) 2026-02-25
DE202018006567U1 (de) 2021-04-01
CN112584875A (zh) 2021-03-30
PT4541379T (pt) 2026-01-29
PL4545100T3 (pl) 2026-03-30
KR20260030955A (ko) 2026-03-06
FI4545100T3 (fi) 2026-03-02
SI4541381T1 (sl) 2026-05-29
JP7796696B2 (ja) 2026-01-09
RS67729B1 (sr) 2026-03-31
LT4541380T (lt) 2026-03-10
EP4545101A2 (en) 2025-04-30
JP7402218B2 (ja) 2023-12-20
IL313560B2 (en) 2025-11-01
RS67864B1 (sr) 2026-04-30
SI4545100T1 (sl) 2026-03-31
AU2025204901B2 (en) 2025-09-18
RS67034B1 (sr) 2025-08-29
ES3063402T3 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
CO2021000506A2 (es) Soluciones de complejos de radionúclidos estables y concentradas
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
BR112017005938A2 (pt) compostos, processo de preparação de composto, processo de preparação de conjugado de galnac e ácido nucleico e usos de composto
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
MX2019002781A (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral.
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
DOP2016000210A (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración, estable
UY35439A (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
AR119655A1 (es) Soluciones de complejos de radionúclidos estables y concentradas
UY36046A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
MX2015005038A (es) Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
BR112017016333A2 (pt) compostos anticâncer
CU24650B1 (es) Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer
MX2017008330A (es) Productos para el suministro de compuestos de diagnóstico/terapeuticos al corazon.
MX390841B (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
IT201700088621A1 (it) Integratori alimentari per uso nel trattamento di patologie associate ad alterazioni del trofismo dei nervi periferici.
ES3063461T3 (en) Stable liquid compositions of pemetrexed
CO2019010663A2 (es) Composición de carbohidratos para la diálisis